Your browser doesn't support javascript.
loading
Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer.
Alexander, John; Mariani, Odette; Meaudre, Celine; Fuhrmann, Laetitia; Xiao, Hui; Naidoo, Kalnisha; Gillespie, Andrea; Roxanis, Ioannis; Vincent-Salomon, Anne; Haider, Syed; Natrajan, Rachael.
Affiliation
  • Alexander J; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
  • Mariani O; Department of Diagnostic and Theranostic Medicine, Department of Pathology, Institute Curie, PSL-Research University, 75005 Paris, France.
  • Meaudre C; Department of Diagnostic and Theranostic Medicine, Department of Pathology, Institute Curie, PSL-Research University, 75005 Paris, France.
  • Fuhrmann L; Department of Diagnostic and Theranostic Medicine, Department of Pathology, Institute Curie, PSL-Research University, 75005 Paris, France.
  • Xiao H; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
  • Naidoo K; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
  • Gillespie A; Department of Cellular Pathology, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
  • Roxanis I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
  • Vincent-Salomon A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
  • Haider S; Department of Diagnostic and Theranostic Medicine, Department of Pathology, Institute Curie, PSL-Research University, 75005 Paris, France.
  • Natrajan R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Cancers (Basel) ; 14(2)2022 Jan 07.
Article in En | MEDLINE | ID: mdl-35053458
ABSTRACT
Mutations and loss of E-cadherin protein expression define the vast majority of invasive lobular carcinomas. In a subset of these cases, the heterogeneous expression of E-cadherin is observed either as wild-type (strong membranous) expression or aberrant expression (cytoplasmic expression). However, it is unclear as to whether the two components would be driven by distinct genetic or epigenetic alterations. Here, we used whole genome DNA sequencing and methylation array profiling of two separately dissected components of nine invasive lobular carcinomas with heterogeneous E-cadherin expression. E-cadherin negative and aberrant/positive components of E-cadherin heterogeneous tumours showed a similar mutational, copy number and promoter methylation repertoire, suggesting they arise from a common ancestor, as opposed to the collision of two independent tumours. We found that the majority of E-cadherin heterogeneous tumours harboured CDH1 mutations in both the E-cadherin negative and aberrant/positive components together with somatic mutations in additional driver genes known to be enriched in both pure invasive carcinomas of no special type and invasive lobular breast cancers, whereas these were less commonly observed in CDH1 wild-type tumours. CDH1 mutant tumours also exhibited a higher mutation burden as well as increased presence of APOBEC-dependent mutational signatures 2 and 13 compared to CDH1 wild-type tumours. Together, our results suggest that regardless of E-cadherin protein expression, tumours showing heterogeneous expression of E-cadherin should be considered as part of the spectrum of invasive lobular breast cancers.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Type: Article Affiliation country: United kingdom